>50x family-selective HPK1 kinase inhibitor

tumor clearance w/ PD-1i (oral 100 mpk BID)

from IRAK4 inhibitor and homology modeling

ACS. Med. Chem. Lett., Feb. 19, 2021

Bristol Myers Squibb, Cambridge, MA

compound-24

6. The Bristol Myers Squibb (BMS) HPK1 kinase inhibitor, “compound 24” is an oral tool compound intended for cancer immunotherapy, with >50x selectivity against family members including GLK. The…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: